pharmaphorum
JANUARY 6, 2022
We spoke with Tanja Dowe, ahead of the annual J.P. Morgan Health Care Conference 2022, about radical innovation in healthcare, including the potential of digital solutions to diagnose disease earlier, using digital therapeutics or preventive digital solutions more efficiently, and making use of technologies that result in accelerated drug discovery and development.
Fierce Healthcare
JANUARY 6, 2022
Forrester: Here are 4 key frontiers for healthcare innovation over the next decade. pminemyer. Thu, 01/06/2022 - 12:54.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 6, 2022
The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Unlike other recent deals however the takeover isn’t focused on adding a pipeline of mRNA candidates, as Indianapolis-based Exelead is a contract development and manufacturing organisation (CDMO) provide derives to other drugmakers.
Fierce Healthcare
JANUARY 6, 2022
Study examines differences in coverage denials for traditional Medicare, MA. agliadkovskaya. Thu, 01/06/2022 - 17:00.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Outsourcing Pharma
JANUARY 6, 2022
Clover Biopharmaceuticals, a clinical-stage biotech developing novel vaccines and biologic therapeutic candidates, has started construction on a new R&D Center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
Fierce Healthcare
JANUARY 6, 2022
CMS proposes Part D price concessions be applied at point-of-sale, new requirements for MA plans. rking. Thu, 01/06/2022 - 17:05.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
JANUARY 6, 2022
Kaufman Hall: Consumers may again be avoiding getting care as hospital margins remain depressed. rking. Thu, 01/06/2022 - 15:28.
pharmaphorum
JANUARY 6, 2022
Fresh from a sizeable funding round that raised $370 million, artificial intelligence-based drug discovery firm Generate Biomedicines has just signed its first major partnering deal with Amgen. The machine learning specialist – founded by venture capital firm Flagship Pioneering in 2018 – is getting $50 million upfront to kick off the alliance, with another £370 million in the offing for up to five programmes.
Fierce Healthcare
JANUARY 6, 2022
Urban Institute: Low-income parents faced more hurdles to afford, receive healthcare in 2021. agliadkovskaya. Thu, 01/06/2022 - 14:39.
Pharma Mirror
JANUARY 6, 2022
ADELAIDE, AUS – TrialWire(TM) is pleased to announce new B-cell lymphoma clinical studies are now available on the TrialWire Platform. More than 6 million people have used TrialWire over the past few years to find clinical trials that are right for them at clinics and specialist centers near them. The studies on TrialWire are available in Australia, New Zealand, and the U.S.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
JANUARY 6, 2022
Babylon Health acquires health kiosk company Higi Health in latest effort to scale in U.S. market. rtorrence. Thu, 01/06/2022 - 11:04.
pharmaphorum
JANUARY 6, 2022
Digital health is unlocking new avenues for innovation across life sciences, and industry leaders are keen to tap into the potential of this burgeoning area. At the 2021 Frontiers Health conference in Milan, thought leaders and industry experts from across the life science industry came together to discuss the future of digital in healthcare. In this Spotlight on Frontiers Health 2021, we present notable highlights and discussions from the conference, including resources from pharmaphorum and Fr
Fierce Healthcare
JANUARY 6, 2022
Chutes & Ladders—Allina Health's new CEO steps up; Another Walmart health exec departs. dmuoio. Thu, 01/06/2022 - 13:59.
pharmaphorum
JANUARY 6, 2022
Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The compound, called H3B-8800, is currently in phase 1 testing in the US and Europe in patients with myelodysplastic syndrome (MDS) who carry mutations in splicing factor 3B subunit 1 (SF3B1) by Eisai’s H3 Biomedicine subsidiary.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
JANUARY 6, 2022
Nomi Health grabs analytics provider Artemis Health to cut employer healthcare costs. rtorrence. Thu, 01/06/2022 - 16:32.
Outsourcing Pharma
JANUARY 6, 2022
This monthâs news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
Pharma Times
JANUARY 6, 2022
The companies share the goal of furthering knowledge around GPCR biology in immune cells in order to better understand a range of immune system disorders.
Outsourcing Pharma
JANUARY 6, 2022
In a report outlining predictions for the coming year, the organization advises industry professionals to brace themselves for supply chain challenges.
Pharma Times
JANUARY 6, 2022
Testing rules for COVID-19 are set to be eased for those who test positive on a lateral flow test but are asymptomatic.
pharmaphorum
JANUARY 6, 2022
Roche’s idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, and could come under renewed pressure if another competitor from PureTech Health gets approved. PureTech is developing a modified version of the active ingredient in Esbriet (pirfenidone) that has just been shown to be less likely to cause gastrointestinal side effects than Roche’s drug in a proof-of-concept trial.
Roots Analysis
JANUARY 6, 2022
Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. These cells are found in abundance in the tumor microenvironment and inflamed areas. The tumor recruits and modulates endogenous myeloid cells to tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells and neutrophils, to sustain an immunosuppressive environment.
pharmaphorum
JANUARY 6, 2022
The Biden administration has launched a fact-finding mission to try to find ways to deploy digital health technologies effectively in community settings, in order to boost “individual wellness and health equity.” The request for information – which appeared in the Federal Register yesterday – was filed by the White House Office of Science and Technology Policy (OSTP) and is aimed particularly at community-based programmes in populations that are currently “underserved” by
pharmaphorum
JANUARY 6, 2022
In the second part of our examination of issues that will shape the course of 2022, we’ll update the ongoing impacts of the pandemic, which have, as they did in 2021, a pervasive effect on both pharma and healthcare issues, with themes we highlighted at the beginning of 2021 continuing their impact. Big Tech makes significant healthcare moves. That Big Tech is planning significant moves into healthcare in 2022 is not a new phenomenon.
Expert insights. Personalized for you.
116 
Let's personalize your content